3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
10
Active not recruiting
8
Recruiting
6
Terminated
5
Withdrawn
1
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
21
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Neoplasm, Residual
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
17
Rituximab
14
Cytarabine
9
Peripheral Blood Stem Cell Transplantation
7
Melphalan
7
Etoposide
7
Filgrastim
6
Dexamethasone
6
fludarabine phosphate
5
fludarabine
5
Radiotherapy
5
Cyclosporine
5
Carmustine
5
ibrutinib
4
Vincristine
4
Prednisone
4
Lenalidomide
4
Doxorubicin
4
Bortezomib
4
Sensitivity and Specificity
3
R-CHOP protocol
3
Mycophenolic Acid
3
Interferon-alpha
3
Indium
3
Cisplatin
3
Busulfan
3
Bendamustine Hydrochloride
3
Antilymphocyte Serum
3
Antigens, CD19
3
sargramostim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma, Mantle-Cell
×
venetoclax
×
Clear all
NCT02471391
2023-08-21
AIM
Peter MacCallum Cancer Centre, Australia
Phase 2
Unknown
37 enrolled